Roth Mkm started coverage on shares of GT Biopharma (NASDAQ:GTBP – Free Report) in a report published on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $11.00 price target ...
OHB-607 (formerly TAK-607), is a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1), the natural version of which is a key driver of fetal growth and development in-utero, and ...
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific ...